



2024 PRIOR AUTHORIZATION REQUEST FORM
Individual and Family Plans

CFTR Modulators

Fax back to: (833) 605-4407

Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Form with fields: Patient Name, Prescriber Name, Member Number, Fax, Phone, Date of Birth, Office Contact, Line of Business, NPI, State Lic ID, Address, City, State ZIP, Primary Phone, Specialty/facility name (if applicable)

REQUEST FOR EXPEDITED REVIEW: By checking this box and signing below, I certify that the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function.

Form with fields: Drug Name, Strength, Directions / SIG

Please attach any pertinent medical history including labs and information for this member that may support approval. Please answer the following questions and sign.

Q1. Is the drug being prescribed by or in consultation with a pulmonologist, endocrinologist, or pediatrician?

Yes No

Q2. Does the patient have a confirmed diagnosis of cystic fibrosis?

Yes No

Q3. Has appropriate genetic testing been conducted? Appropriate lab work must be attached.

Yes No

Q4. Has baseline liver function (including alanine aminotransferase [ALT], aspartate aminotransferase [AST] and bilirubin) been assessed prior to initiation of treatment? Labs must be attached.

Yes No

Q5. GENETIC TESTING: For KALYDECO: Does genetic testing show the patient has one mutation in the CFTR gene that is responsive to ivacaftor based on clinical and/or in vitro assay



2024 PRIOR AUTHORIZATION REQUEST FORM
Individual and Family Plans

CFTR Modulators

Fax back to: (833) 605-4407

Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Form fields for Patient Name and Prescriber Name

data?
For ORKAMBI: Does genetic testing show the patient is homozygous for the F508del mutation in the CFTR gene?
For TRIKAFTA: Does genetic testing show the patient has at least one F508del mutation in the CFTR gene or a mutation in the CFTR gene that is responsive based on in vitro data?
[] Yes [] No

Q6. Additional Information:

Prescriber Signature

Date

2024 Prior Authorization Request